Relationships between circulating matrix metalloproteinase-2 and-9 and renal function in patients with chronic kidney disease

被引:70
作者
Chang, HR
Yang, SF
Li, ML
Lin, CC
Hsieh, YS [1 ]
Lian, JD
机构
[1] Chung Shan Med Univ Hosp, Dept Internal Med, Div Nephrol, Taichung 402, Taiwan
[2] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung 402, Taiwan
[3] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan
[4] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung 402, Taiwan
关键词
matrix metalloproteinase; serum creatinine; chronic kidney disease;
D O I
10.1016/j.cca.2005.10.007
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: It has been proven that extracellular matrix turnover is involved in the pathogenesis of various renal fibrosis diseases. Matrix metalloproteinase-2 and -9 (MMP-2 and -9) are the extracellular matrix degrading enzymes that are believed to play important roles in renal diseases. However, the relationship of circulating levels of MMP-2, -9 and serum creatinine in the patients of chronic kidney disease (CKD) has not yet been investigated. Methods: Gelatin zymography and ELISA were employed to measure MMP-2 and MMP-9 activities in the plasma samples of 60 CKD patients and 40 control subjects. Results: Serum creatinine concentrations and MMP-2 activities were significantly higher (p < 0.001) while MMP-9 activity and creatinine clearance (CCr) were significantly lower (p < 0.05 and p < 0.001, respectively) in CKD patients, as compared with those of control subjects. In addition, serum creatinine concentrations correlated with MMP-2 activity (R = 0.288, p < 0.05) and inversely correlated with that of MMP-9 (R = 0.344, p < 0.01). Conclusions: This Study demonstrated a correlation between MMP-2, -9 and serum creatinine in CKD patients to suggest that MMP-2 and MMP-9 might contribute in the pathogenesis of CKD. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:243 / 248
页数:6
相关论文
共 38 条
[1]  
Akiyama K, 1997, RES COMMUN MOL PATH, V95, P115
[2]   Fibrosis and altered matrix degradation [J].
Arthur, MJP .
DIGESTION, 1998, 59 (04) :376-380
[3]   Should the K/DOQI definition of chronic kidney disease be changed? Pro [J].
Chen, MLW ;
Hsu, CY .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 42 (04) :623-625
[4]   Relationship between matrix metalloproteinase-2 activity and cystatin C levels in patients with hepatic disease [J].
Chen, TY ;
Hsieh, YS ;
Yang, CC ;
Wang, CP ;
Yang, SF ;
Cheng, YW ;
Chiou, HL .
CLINICAL BIOCHEMISTRY, 2005, 38 (07) :632-638
[5]   Effect of hemodialysis on the plasma level of type IV collagenases and their inhibitors [J].
Chou, FP ;
Chu, SC ;
Cheng, MC ;
Yang, SF ;
Cheung, WN ;
Chiou, HL ;
Hsieh, YS .
CLINICAL BIOCHEMISTRY, 2002, 35 (05) :383-388
[6]   The clinical significance of gelatinase B in gouty arthritis of the knee [J].
Chu, SC ;
Yang, SF ;
Lue, KH ;
Hsieh, YS ;
Hsiao, TY ;
Lu, KH .
CLINICA CHIMICA ACTA, 2004, 339 (1-2) :77-83
[7]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[8]   THE PURIFICATION AND CHARACTERIZATION OF A GLOMERULAR-BASEMENT-MEMBRANE-DEGRADING NEUTRAL PROTEINASE FROM RAT MESANGIAL CELLS [J].
DAVIES, M ;
THOMAS, GJ ;
MARTIN, J ;
LOVETT, DH .
BIOCHEMICAL JOURNAL, 1988, 251 (02) :419-425
[9]   PROTEINASES AND GLOMERULAR MATRIX TURNOVER [J].
DAVIES, M ;
MARTIN, J ;
THOMAS, GJ ;
LOVETT, DH .
KIDNEY INTERNATIONAL, 1992, 41 (03) :671-678
[10]   Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM [J].
DelPrete, D ;
Anglani, F ;
Forino, M ;
Ceol, M ;
Fioretto, P ;
Nosadini, R ;
Baggio, B ;
Gambaro, G .
DIABETOLOGIA, 1997, 40 (12) :1449-1454